BusinessCellular Biomedicine Group (CBMG) and GE Healthcare Life Sciences China Announce Strategic Partnership to Establish Joint Technology Laboratory to Develop Control Processes for the Manufacture of CAR-T and Stem Cell TherapiesBy Nasdaq OMXApr 10, 2017, 12:08 PM UTC
BusinessCellular Biomedicine Group (CBMG) Approved to Commence Phase I Trial (CARD-1) for C-CAR011 in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL) in ChinaBy Nasdaq OMXNov 29, 2016, 12:16 PM UTC
BusinessCellular Biomedicine Group to Present at the 2016 World Stem Cell SummitBy Nasdaq OMXNov 28, 2016, 12:36 PM UTC
BusinessUPDATE -- Cellular Biomedicine Group Reports Second Quarter and First Half 2016 Financial Results and Business HighlightsBy Nasdaq OMXAug 9, 2016, 1:37 PM UTC
BusinessCellular Biomedicine Group Reports Second Quarter and First Half 2016 Financial Results and Business HighlightsBy Nasdaq OMXAug 9, 2016, 10:26 AM UTC
BusinessCellular Biomedicine Group Announces Closing of $43.13 Million Strategic Investment from Dangdai International Group Co., Limited, a Wholly-Owned Hong Kong Subsidiary of Wuhan Dangdai Science & Technology Industries Group Inc.By Nasdaq OMXApr 19, 2016, 12:30 PM UTC
BusinessCellular Biomedicine Group Reports Full-Year 2015 Financial Results and Recent Operational ProgressBy Nasdaq OMXMar 14, 2016, 11:00 AM UTC
BusinessCellular Biomedicine Group Announces a $43.13 Million Strategic Investment From Dangdai International Group Co., Limited, a Wholly Owned Hong Kong Subsidiary of Wuhan Dangdai Science & Technology Industries Group Inc.By Nasdaq OMXFeb 4, 2016, 2:09 PM UTC
